Valuation: Guided Therapeutics Inc

Market Cap 28.96M 25.33M 23.37M 21.58M 40.95M 2.76B 41.64M 279M 110M 1.36B 109M 106M 4.68B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 31.84M 27.85M 25.69M 23.72M 45.02M 3.04B 45.77M 307M 121M 1.5B 120M 117M 5.14B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 70 05/03/2023
Chief Tech/Sci/R&D Officer 70 01/12/2010
Director TitleAgeSince
Director/Board Member 70 30/11/2016
Director/Board Member 76 09/04/2006
Chairman 67 30/09/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.45%+0.69%+21.20%+0.21% 196B
-1.16%-4.51%-20.56%+17.03% 144B
+1.57%+0.57%-2.83%-16.40% 141B
-0.49%-0.82%-56.62%-14.66% 66.54B
+0.96%-2.29%+18.14%-0.96% 53.09B
+0.61%-1.09%-24.93%-31.31% 44.12B
+0.52%+2.75%+8.93%+11.91% 37.93B
-0.19%-0.75%+6.66%+39.97% 36.96B
0.00%-1.32%-13.88%-20.80% 29.43B
Average +0.25%-0.75%-7.10%-1.67% 83.21B
Weighted average by Cap. +0.27%-0.83%-3.92%-1.21%

Financials

2024 2025
Net sales 7K 6.12K 5.65K 5.22K 9.9K 668K 10.06K 67.48K 26.5K 329K 26.28K 25.71K 1.13M 767K 671K 619K 572K 1.08M 73.15M 1.1M 7.39M 2.9M 36.04M 2.88M 2.82M 124M
Net income -2.42M -2.11M -1.95M -1.8M -3.42M -231M -3.47M -23.3M -9.15M -114M -9.08M -8.88M -390M -3.2M -2.8M -2.58M -2.38M -4.52M -305M -4.59M -30.81M -12.1M -150M -12M -11.74M -516M
Net Debt 1.77M 1.55M 1.43M 1.32M 2.5M 169M 2.55M 17.07M 6.7M 83.21M 6.65M 6.5M 286M 2.88M 2.52M 2.32M 2.14M 4.07M 274M 4.13M 27.72M 10.89M 135M 10.8M 10.56M 465M
Logo Guided Therapeutics Inc
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
-